Moorestown, New Jersey, United States

7322321334

seeking biotech alpha

seeking biotech alpha 寻求生物技术阿尔法 4/7/2020 the heart of biotech™

seeking biotech alpha 寻求生物技术阿尔法 4/7/2020 the heart of biotech™

seeking biotech alpha 寻求生物技术阿尔法 4/7/2020 the heart of biotech™ seeking biotech alpha 寻求生物技术阿尔法 4/7/2020 the heart of biotech™

seeking biotech alpha February 2019 insight

Sprycel (dasatinib) in Combination with Chemotherapy

Sprycel (dasatinib) in Combination with Chemotherapy

Sprycel (dasatinib) in Combination with Chemotherapy

image193

European Commission Approves Bristol-Myers Squibb’s Sprycel (dasatinib) in Combination with Chemotherapy for Treatment of Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Mon February 11, 2019 6:59 AM|Business Wire|About: BMY 

KEYTRUDA® (pembrolizumab)

Sprycel (dasatinib) in Combination with Chemotherapy

Sprycel (dasatinib) in Combination with Chemotherapy

image194

FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Mon February 11, 2019 6:45 AM|Business Wire|About: MRK 

PRALUENT® (ALIROCUMAB)

Sprycel (dasatinib) in Combination with Chemotherapy

AbbVie (ABBV), Teneobio, Inc.

image195

 February 11, 2019 at 6:59 AM EST 

REGENERON AND SANOFI OFFER PRALUENT® (ALIROCUMAB) AT A NEW REDUCED U.S. LIST PRICE

TARRYTOWN, N.Y. and BRIDGEWATER, N.J., Feb. 11, 2019 /PRNewswire/ --

This is the latest step by the companies to help make Praluent more accessible and affordable for appropriate patients

Beginning in early March 2019, new U.S. National Drug Code (NDC) options will be available at approximately 60% less than the original price

AbbVie (ABBV), Teneobio, Inc.

ADU-S100 (MIW815), a stimulator of interferon genes (STING) pathway activator + YERVOY® (ipilimumab)

AbbVie (ABBV), Teneobio, Inc.

image196

AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma

Mon February 11, 2019 8:00 AM|PR Newswire|About: ABBV 

ADU-S100 (MIW815), a stimulator of interferon genes (STING) pathway activator + YERVOY® (ipilimumab)

ADU-S100 (MIW815), a stimulator of interferon genes (STING) pathway activator + YERVOY® (ipilimumab)

ADU-S100 (MIW815), a stimulator of interferon genes (STING) pathway activator + YERVOY® (ipilimumab)

image197

 Aduro Announces First Patient Dosed in Phase 1 Study of ADU-S100 (MIW815) in Combination with YERVOY (ipilimumab) for the Treatment of Relapsed and Refractory Melanoma

Mon February 11, 2019 8:00 AM|GlobeNewswire|About: ADRO 

BAVENCIO® (avelumab) Plus INLYTA® (axitinib)

ADU-S100 (MIW815), a stimulator of interferon genes (STING) pathway activator + YERVOY® (ipilimumab)

ADU-S100 (MIW815), a stimulator of interferon genes (STING) pathway activator + YERVOY® (ipilimumab)

image198

 FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma

Mon February 11, 2019 5:44 PM|PR Newswire|About: MKKGY, PFE 

seeking biotech alpha February 2019 insight

Brineura® (cerliponase alfa)

SB-318 Zinc Finger Nuclease (ZFN) In Vivo Genome Editing

SB-318 Zinc Finger Nuclease (ZFN) In Vivo Genome Editing

 BioMarin Announces Ongoing Study Demonstrates Durable Treatment Benefit from Brineura® (cerliponase alfa) for 3 Years

Thu February 7, 2019 4:28 PM|PR Newswire|About: BMRN 

SB-318 Zinc Finger Nuclease (ZFN) In Vivo Genome Editing

SB-318 Zinc Finger Nuclease (ZFN) In Vivo Genome Editing

SB-318 Zinc Finger Nuclease (ZFN) In Vivo Genome Editing

image199

 Sangamo Announces Interim Results Of Phase 1/2 EMPOWERS Study Evaluating SB-318 Zinc Finger Nuclease (ZFN) In Vivo Genome Editing Demonstrating Increased Leukocyte IDUA Activity In Patients With MPS I

Thu February 7, 2019 11:00 AM|PR Newswire|About: SGMO 

Regeneron Pharmaceutical (REGN)

SB-318 Zinc Finger Nuclease (ZFN) In Vivo Genome Editing

ADCETRIS® (Brentuximab Vedotin)

image200

 February 6, 2019 at 6:30 AM EST 

REGENERON REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL AND OPERATING RESULTS

TARRYTOWN, N.Y., Feb. 6, 2019 /PRNewswire/ --

  • Fourth quarter 2018 revenues were $1.93 billion, an increase of 22%

ADCETRIS® (Brentuximab Vedotin)

PRGN-3005 UltraCAR-T™ to Treat Advanced Stage Platinum Resistant Ovarian Cancer Patients

ADCETRIS® (Brentuximab Vedotin)

image201

Seattle Genetics Achieves $30 Million Milestone Payment for European Commission Approval of ADCETRIS® (Brentuximab Vedotin) in Frontline Hodgkin Lymphoma

Mon February 11, 2019 8:00 AM|Business Wire|About: SGEN 

PRGN-3005 UltraCAR-T™ to Treat Advanced Stage Platinum Resistant Ovarian Cancer Patients

PRGN-3005 UltraCAR-T™ to Treat Advanced Stage Platinum Resistant Ovarian Cancer Patients

PRGN-3005 UltraCAR-T™ to Treat Advanced Stage Platinum Resistant Ovarian Cancer Patients

image202

 Precigen Announces Clearance of IND to Initiate Phase 1 Study for First-in-Class PRGN-3005 UltraCAR-T™ to Treat Advanced Stage Platinum Resistant Ovarian Cancer Patients

Mon February 11, 2019 7:30 AM|PR Newswire|About: XON 

EYLEA® (aflibercept)

PRGN-3005 UltraCAR-T™ to Treat Advanced Stage Platinum Resistant Ovarian Cancer Patients

PRGN-3005 UltraCAR-T™ to Treat Advanced Stage Platinum Resistant Ovarian Cancer Patients

image203

 One-Year Results from Positive Phase 3 EYLEA Trial in Diabetic Retinopathy Presented at Angiogenesis Symposium

Sat February 9, 2019 4:30 PM|PR Newswire|About: REGN

TARRYTOWN, N.Y., Feb. 9, 2019 /PRNewswire/ -- 

seeking biotech alpha February 2019 insight

Fasenra (benralizumab)

ADYNOVATE® [Antihemophilic Factor [Recombinant]

Cablivi® (caplacizumab-yhdp)

image204

 US FDA grants Fasenra Orphan Drug Designation for hypereosinophilic syndrome   PUBLISHED6 February 2019 


 AstraZeneca Group plc (AZN) 

Cablivi® (caplacizumab-yhdp)

ADYNOVATE® [Antihemophilic Factor [Recombinant]

Cablivi® (caplacizumab-yhdp)

image205

FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)

Wed February 6, 2019 11:53 AM|PR Newswire|About: SNY 

Ruxolitinib (Jakafi®)

Boston Scientific Corporation (BSX)

Pipeline Flex embolization device

image209

 Incyte Announces U.S. FDA Has Extended the Review Period for Ruxolitinib (Jakafi®) in Acute Graft-Versus-Host Disease

Thu February 7, 2019 7:00 AM|Business Wire|About: INCY 

seeking biotech alpha February 2019 insight

baricitinib

KEYTRUDA® (pembrolizumab)

KEYTRUDA® (pembrolizumab)

image210

 Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis

Mon February 4, 2019 6:45 AM|PR Newswire|About: INCY, LLY 

TECNIS Eyhance IOL

KEYTRUDA® (pembrolizumab)

Praluent® (alirocumab) Injection

image212

Johnson & Johnson Vision Announces Availability in Europe of TECNIS Eyhance IOL, a Next-Generation Monofocal Intraocular Lens for Patients with Cataracts

Mon February 4, 2019 2:00 AM|PR Newswire|About: JNJ 

Praluent® (alirocumab) Injection

ENB-003, a first-in class endothelin B receptor ("ETBR") inhibitor & KEYTRUDA® (pembrolizumab)

Praluent® (alirocumab) Injection

image213

 CHMP Recommends Approval of Praluent® (alirocumab) Injection to Reduce Cardiovascular Risk in People with Established Atherosclerotic Cardiovascular Disease

Mon February 4, 2019 12:59 AM|PR Newswire|About: REGN 

https://www.praluent.com/

ENB-003, a first-in class endothelin B receptor ("ETBR") inhibitor & KEYTRUDA® (pembrolizumab)

ENB-003, a first-in class endothelin B receptor ("ETBR") inhibitor & KEYTRUDA® (pembrolizumab)

ENB-003, a first-in class endothelin B receptor ("ETBR") inhibitor & KEYTRUDA® (pembrolizumab)

image214

  • ENB Therapeutics Announces Clinical Trial Collaboration with Merck to Evaluate ENB-003 in combination with KEYTRUDA(R) (pembrolizumab) for Advanced Solid Tumors

Mon February 4, 2019 8:00 AM|Accesswire|About: MRK 

Alexion Pharmaceuticals, Inc. (ALXN)

ENB-003, a first-in class endothelin B receptor ("ETBR") inhibitor & KEYTRUDA® (pembrolizumab)

ENB-003, a first-in class endothelin B receptor ("ETBR") inhibitor & KEYTRUDA® (pembrolizumab)

image215

 Alexion Pharmaceuticals, Inc. 2018 Q4 - Results - Earnings Call Slides

Feb. 4, 2019 10:05 AM ET | About: Alexion Pharmaceuticals, Inc. (ALXN) 

seeking biotech alpha February 2019 insight

Merck & Co Inc. (MRK)

Forxiga (dapagliflozin)

AJOVY® (fremanezumab)

image217

Merck Announces Fourth-Quarter and Full-Year 2018 Financial Results

Fri February 1, 2019 6:45 AM|Business Wire|About: MRK 

 

EPS of $1.04 beats by $0.01

Revenue of $11B (+ 5.5% Y/Y) beats by $50M

Forxiga (dapagliflozin)

Forxiga (dapagliflozin)

Bausch Health Companies Inc. (BHC), https://www.sightmatters.com/

image218

 European advisory group backs AstraZeneca's Forxiga in T1D

Feb. 1, 2019 8:58 AM ET|About: AstraZeneca Group plc (AZN)|By: , SA News Editor  

Bausch Health Companies Inc. (BHC), https://www.sightmatters.com/

Bausch Health Companies Inc. (BHC), https://www.sightmatters.com/

Bausch Health Companies Inc. (BHC), https://www.sightmatters.com/

image219

 Bausch + Lomb Launches SightMatters.com To Help People Living With Age-Related Macular Degeneration Take Control Of Their Condition

Mon February 4, 2019 8:00 AM|Canada Newswire|About: BHC 

https://www.sightmatters.com/

Hemlibra®, a treatment for hemophilia A

Bausch Health Companies Inc. (BHC), https://www.sightmatters.com/

Hemlibra®, a treatment for hemophilia A

image220

 Chugai’s Hemlibra® Gains Positive CHMP Opinion in Severe Hemophilia A Without Inhibitors

Sun February 3, 2019 8:00 PM|Business Wire|About: CHGCY, RHHBY 

Kadcyla® (ado-trastuzumab emtansine)

Bausch Health Companies Inc. (BHC), https://www.sightmatters.com/

Hemlibra®, a treatment for hemophilia A

image221

 Genentech Submits Supplemental Biologics License Application to FDA for Kadcyla for Adjuvant Treatment of People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment

Tue February 5, 2019 1:00 AM|Business Wire|About: RHHBY 

seeking biotech alpha January 2019 insight

ALIMTA® (pemetrexed for injection) in combination with KEYTRUDA® (pembrolizumab)

mRNA-2752, combined with AstraZeneca's (AZN +1.7%) IMFINZI (durvalumab) or tremelimumab

ALIMTA® (pemetrexed for injection) in combination with KEYTRUDA® (pembrolizumab)

image222

FDA Expands Lilly's ALIMTA® (pemetrexed) Label with Combination of KEYTRUDA® (pembrolizumab) and Platinum Chemotherapy for the First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer

Thu January 31, 2019 6:45 AM|PR Newswire|About: LLY 

ABIOMED, Inc. (ABMD)

mRNA-2752, combined with AstraZeneca's (AZN +1.7%) IMFINZI (durvalumab) or tremelimumab

ALIMTA® (pemetrexed for injection) in combination with KEYTRUDA® (pembrolizumab)

ABIOMED, Inc. 2019 Q3 - Results - Earnings Call Slides

Jan. 31, 2019 9:55 AM ET|2 comments | About: ABIOMED, Inc. (ABMD) 

mRNA-2752, combined with AstraZeneca's (AZN +1.7%) IMFINZI (durvalumab) or tremelimumab

mRNA-2752, combined with AstraZeneca's (AZN +1.7%) IMFINZI (durvalumab) or tremelimumab

mRNA-2752, combined with AstraZeneca's (AZN +1.7%) IMFINZI (durvalumab) or tremelimumab

image223

Moderna up 15% on mRNA-2752 data

Jan. 31, 2019 1:06 PM ET|By: , SA News Editor  

Impella Connect

cobas® HPV on the cobas® 6800/8800 Systems for cervical cancer screening in Canada.

mRNA-2752, combined with AstraZeneca's (AZN +1.7%) IMFINZI (durvalumab) or tremelimumab

image224

 Impella Connect Achieves Regulatory Milestone

Cloud-based monitoring platform gains CE Mark, adding to FDA PMA approval

 Impella Connect allows medical professionals to view the Impella console, in real-time, from any Internet-connected computer or mobile device.  

 anuary 31, 2019 08:00 AM Eastern Standard Time

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ:ABMD)

cobas® HPV on the cobas® 6800/8800 Systems for cervical cancer screening in Canada.

cobas® HPV on the cobas® 6800/8800 Systems for cervical cancer screening in Canada.

cobas® HPV on the cobas® 6800/8800 Systems for cervical cancer screening in Canada.

image225

January is cervical cancer awareness month. Roche is committed to cervical cancer prevention and is proud to announce that the new Roche cobas® HPV assay for use on the cobas® 6800/8800 Systems is now Health Canada approved

Thu January 31, 2019 5:18 PM|Canada Newswire|About: CHGCY, RHHBY 

Vizimpro® (dacomitinib)

cobas® HPV on the cobas® 6800/8800 Systems for cervical cancer screening in Canada.

cobas® HPV on the cobas® 6800/8800 Systems for cervical cancer screening in Canada.

image226

Pfizer Receives Positive CHMP Opinion for Vizimpro® (dacomitinib) for the First-line Treatment of Adult Patients with Locally Advanced Or Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations

Fri February 1, 2019 9:17 AM|Business Wire|About: PFE 

seeking biotech alpha January 2019 insight

superDimension(TM)

V114, the company’s investigational 15-valent pneumococcal conjugate vaccine,

V114, the company’s investigational 15-valent pneumococcal conjugate vaccine,

 Medtronic Announces Positive Results from the Largest ENB Study to Aid in Lung Cancer Diagnosis, Staging, and Treatment Preparation in a Single Minimally Invasive Procedure

Wed January 30, 2019 8:30 AM|InPublic US|About: MDT 

V114, the company’s investigational 15-valent pneumococcal conjugate vaccine,

V114, the company’s investigational 15-valent pneumococcal conjugate vaccine,

V114, the company’s investigational 15-valent pneumococcal conjugate vaccine,

image227

Merck Receives Breakthrough Therapy Designation from FDA for V114, the Company’s Investigational 15-Valent Conjugate Vaccine for the Prevention of Invasive Pneumococcal Disease, in Infants, Children, and Adolescents

Wed January 30, 2019 6:45 AM|Business Wire|About: MRK 

ERLEADA (apalutamide)

V114, the company’s investigational 15-valent pneumococcal conjugate vaccine,

Medtronic Valiant(TM) Captivia(TM)

image228

 Johnson & Johnson's Erleada successful in late-stage metastatic prostate cancer study

Jan. 30, 2019 8:57 AM ET|About: Johnson & Johnson (JNJ)|By: , SA News Editor  

Medtronic Valiant(TM) Captivia(TM)

Medtronic Valiant(TM) Captivia(TM)

Medtronic Valiant(TM) Captivia(TM)

image229

Medtronic Valiant(TM) Captivia(TM) Demonstrates Durability, Safety, and Efficacy at Five Years in Transection Patients

Wed January 30, 2019 10:30 AM|InPublic US|About: MDT 

Amgen Inc. (AMGN)

Medtronic Valiant(TM) Captivia(TM)

Amgen Inc. (AMGN)

image230

 Amgen Inc. 2018 Q4 - Results - Earnings Call Slides

Jan. 29, 2019 9:10 PM ET | About: Amgen Inc. (AMGN) 

Novartis AG (NVS)

Medtronic Valiant(TM) Captivia(TM)

Amgen Inc. (AMGN)

image231

 Novartis expects to launch at least 10 blockbusters by 2020

Jan. 30, 2019 11:33 AM ET|About: Novartis AG (NVS)|By: , SA News Editor 

seeking biotech alpha January 2019 insight

tanezumab 2.5 mg or 5 mg

dengue vaccine candidate (TAK-003)

dengue vaccine candidate (TAK-003)

image233

 Pfizer and Lilly Announce Top-Line Results From Second Phase 3 Study of Tanezumab in Osteoarthritis Pain

Tue January 29, 2019 6:30 AM|Business Wire|About: LLY, PFE 

Biogen Inc. (BIIB)

dengue vaccine candidate (TAK-003)

TREMFYA (guselkumab).

image234

 Biogen beats Q4 consensus

Jan. 29, 2019 7:40 AM ET|About: Biogen Inc. (BIIB)|By: , SA News Editor 

Biogen (BIIB) Q4 results: Revenues: $3,526.3M (+6.6%); Product Sales: $2,825.7M (+4.2%); Anti-CD20 Revenues: $534.9M (+28.9%)

TREMFYA (guselkumab).

TREMFYA (guselkumab).

TREMFYA (guselkumab).

image235

FDA OKs patient-controller injector for J&J's Tremfya

Jan. 29, 2019 3:51 PM ET|By: , SA News Editor  

Pfizer Inc. (PFE)

TREMFYA (guselkumab).

Amgen Inc. (AMGN)

PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2018 RESULTS

Tue January 29, 2019 6:45 AM|Business Wire|About: PFE 

EPS of $0.64 beats by $0.01

Revenue of $13.98B (+ 2.0% Y/Y) beats by $80M

Amgen Inc. (AMGN)

TREMFYA (guselkumab).

Amgen Inc. (AMGN)

image236

 Amgen Reports Fourth Quarter And Full Year 2018 Financial Results

Tue January 29, 2019 4:01 PM|PR Newswire|About: AMGN 

 

Amgen (NASDAQ:AMGN): Q4 Non-GAAP EPS of $3.42 beats by $0.15; GAAP EPS of $3.01 beats by $0.14.

Revenue of $6.23B (+7.4% Y/Y) beats by $390M

seeking biotech alpha January 2019 insight

Repatha® (evolocumab)

Intuitive Surgical (NASDAQ:ISRG)

Intuitive Surgical (NASDAQ:ISRG)

image237

Amgen Receives NMPA Approval For Repatha® (evolocumab) In China To Reduce The Risk Of Cardiovascular Events

Thu January 24, 2019 4:00 PM|PR Newswire|About: AMGN 

Intuitive Surgical (NASDAQ:ISRG)

Intuitive Surgical (NASDAQ:ISRG)

Intuitive Surgical (NASDAQ:ISRG)

image238

Intuitive Surgical Q4 EPS miss pressures shares, down 2%

Jan. 24, 2019 4:17 PM ET|About: Intuitive Surgical, Inc. (ISRG)|By: , SA News Editor 

Mazor X Stealth(TM)

IMBRUVICA® (ibrutinib) Plus Obinutuzumab (GAZYVA®)

Rubraca®▼ (rucaparib)

 Medtronic Announces U.S. Commercial Launch of Mazor X Stealth(TM) Edition for Robotic-Assisted Spine Surgery

Mon January 28, 2019 7:00 AM|InPublic US|About: MDT 

KALYDECO® (ivacaftor)

IMBRUVICA® (ibrutinib) Plus Obinutuzumab (GAZYVA®)

IMBRUVICA® (ibrutinib) Plus Obinutuzumab (GAZYVA®)

image241

Health Canada Grants Market Authorization for KALYDECO® (ivacaftor) in Children Ages 12 to <24 months with Certain Mutations in the CFTR Gene

Mon January 28, 2019 9:17 AM|Business Wire|About: VRTX 

seeking biotech alpha January 2019 insight

ABP 798, a biosimilar candidate to RITUXAN® (rituximab)

ABP 798, a biosimilar candidate to RITUXAN® (rituximab)

ABP 798, a biosimilar candidate to RITUXAN® (rituximab)

image242

Amgen And Allergan Announce Positive Top-Line Results From Phase 1/ Phase 3 Study Of ABP 798, Biosimilar Candidate To Rituximab

Thu January 24, 2019 9:00 AM|PR Newswire|About: AGN, AMGN 

Varian Medical Systems, Inc. (VAR)

ABP 798, a biosimilar candidate to RITUXAN® (rituximab)

ABP 798, a biosimilar candidate to RITUXAN® (rituximab)

Varian Medical Systems, Inc. 2019 Q1 - Results - Earnings Call Slides

Jan. 23, 2019 11:16 PM ET | About: Varian Medical Systems, Inc. (VAR) 

two DNA-dependent protein kinase (DNA-PK) inhibitors - M9831 (formerly known as VX-984)

two DNA-dependent protein kinase (DNA-PK) inhibitors - M9831 (formerly known as VX-984)

two DNA-dependent protein kinase (DNA-PK) inhibitors - M9831 (formerly known as VX-984)

image244

Merck Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors

Thu January 24, 2019 8:00 AM|Canada Newswire|About: MRK 

Gilead Sciences, Inc. (GILD), Agenus (AGEN)

two DNA-dependent protein kinase (DNA-PK) inhibitors - M9831 (formerly known as VX-984)

Gilead Sciences, Inc. (GILD), Agenus (AGEN)

image245

Agenus Closes $150 Million Immuno-Oncology Transaction with Gilead

Thu January 24, 2019 8:30 AM|PR Newswire|About: AGEN, GILD 

BD Nano™ 2nd gen pen needles

two DNA-dependent protein kinase (DNA-PK) inhibitors - M9831 (formerly known as VX-984)

Gilead Sciences, Inc. (GILD), Agenus (AGEN)

image246

BD Launches Ergonomic Pen Needle Technology to Help Optimize Injection Technique

Thu January 24, 2019 6:59 AM|PR Newswire|About: BDX 

seeking biotech alpha January 2019 insight

BLINCYTO® (blinatumomab)

itacitinib, Incyte’s novel and selective JAK1 inhibitor

itacitinib, Incyte’s novel and selective JAK1 inhibitor

image247

European Commission Approves BLINCYTO® (blinatumomab) In Patients With Philadelphia Chromosome Negative Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia

Tue January 22, 2019 9:00 AM|PR Newswire|About: AMGN 

itacitinib, Incyte’s novel and selective JAK1 inhibitor

itacitinib, Incyte’s novel and selective JAK1 inhibitor

itacitinib, Incyte’s novel and selective JAK1 inhibitor

image248

Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib for Chronic Graft-Versus-Host Disease

Tue January 22, 2019 7:30 AM|Business Wire|About: INCY 

Johnson & Johnson (JNJ)

Xultophy® (insulin degludec + liraglutide injection)

Xultophy® (insulin degludec + liraglutide injection)

image251

Johnson & Johnson 2018 Q4 - Results - Earnings Call Slides

Jan. 22, 2019 2:56 PM ET | About: Johnson & Johnson (JNJ) 

Xultophy® (insulin degludec + liraglutide injection)

Xultophy® (insulin degludec + liraglutide injection)

Xultophy® (insulin degludec + liraglutide injection)

image252

 Xultophy® now available in Canada to support improved glycemic control, an issue facing 50 per cent of Canadians with type 2 diabetes

Wed January 23, 2019 8:00 AM|Canada Newswire|About: NVO 

seeking biotech alpha January 2019 insight

TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™

TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™

TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™

image253

Abbott Offers a New Option for Physicians Treating Patients with Atrial Fibrillation

Mon January 21, 2019 9:00 AM|PR Newswire|About: ABT 

CYRAMZA® (ramucirumab)

TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™

TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™

image254

Lilly Phase 3 REACH-2 Trial Data Published in The Lancet Oncology Shows Improvement in Overall Survival with CYRAMZA® (ramucirumab) in Second-Line AFP-High Hepatocellular Carcinoma Patients

Fri January 18, 2019 7:02 PM|PR Newswire|About: LLY 

GW Pharmaceuticals (NASDAQ:GWPH)

TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™

GW Pharmaceuticals (NASDAQ:GWPH)

image255

GW Pharma files for mixed shelf offering

Jan. 19, 2019 2:18 PM ET|About: GW Pharmaceuticals plc (GWPH)|By: , SA News Editor 

VICI VENOUS STENT® System

ORKAMBI (lumacaftor/ivacaftor)

GW Pharmaceuticals (NASDAQ:GWPH)

image256

 VICI VENOUS STENT® System Demonstrates Positive Clinical Outcomes in Patients with Deep Venous Blockages

Tue January 22, 2019 6:11 AM|PR Newswire|About: BSX 

seeking biotech alpha January 2019 insight

Boston Scientific Corporation (BSX)

Boston Scientific Corporation (BSX)

Boston Scientific Corporation (BSX)

image261

 Boston Scientific (BSX) Investor Presentation - Slideshow

Jan. 18, 2019 12:20 PM ET|1 comment | About: Boston Scientific Corporation (BSX) 

Immunomedics (IMMU)

Boston Scientific Corporation (BSX)

Ibrutinib (IMBRUVICA®)

image263

 FDA rejection of Immunomedics' TNBC candidate not related to clinical data

Jan. 18, 2019 1:56 PM ET|By: , SA News Editor  

seeking biotech alpha January 2019 insight

SynchroMed(TM) II

Johnson & Johnson (NYSE:JNJ) will collaborate with Apple

Johnson & Johnson (NYSE:JNJ) will collaborate with Apple

image264

Medtronic Enrolls First Patient in Clinical Study to Assess Pain Control and Oral Opioid Elimination with Targeted Drug Delivery

Thu January 17, 2019 9:00 AM|InPublic US|About: MDT 

Johnson & Johnson (NYSE:JNJ) will collaborate with Apple

Johnson & Johnson (NYSE:JNJ) will collaborate with Apple

Johnson & Johnson (NYSE:JNJ) will collaborate with Apple

image265

 J&J teams up with Apple in heart health program

Jan. 17, 2019 9:25 AM ET|By: , SA News Editor  

Guselkumab (Tremfya(R))

Zynquista(TM) (sotagliflozin)

Guselkumab (Tremfya(R))

image267

MorphoSys Announces that its Licensee Janssen has Expanded Clinical Development of Guselkumab (Tremfya(R)) into Ulcerative Colitis

Thu January 17, 2019 4:25 PM|Accesswire|About: JNJ, MOR, MPSYF 

Sacituzumab Govitecan

Zynquista(TM) (sotagliflozin)

Zynquista(TM) (sotagliflozin)

image268

 Immunomedics Receives Complete Response Letter From FDA for Sacituzumab Govitecan Biologics License Application

Thu January 17, 2019 8:12 PM|GlobeNewswire|About: IMMU

MORRIS PLAINS, N.J., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (IMMU), (NASDAQ: IMMU) 

Zynquista(TM) (sotagliflozin)

Zynquista(TM) (sotagliflozin)

Zynquista(TM) (sotagliflozin)

image269

 Sanofi: FDA advisory committee votes on Zynquista(TM) (sotagliflozin) as treatment for adults with type 1 diabetes

Thu January 17, 2019 6:20 PM|GlobeNewswire|About: SNY 

seeking biotech alpha January 2019 insight

OPSUMIT® (Macitentan)

Tecentriq Plus Chemotherapy (Abraxane and Carboplatin)

OPSUMIT® (Macitentan)

image270

 Actelion Receives Complete Response Letter from U.S. FDA for OPSUMIT® (Macitentan) Supplemental New Drug Application

Wed January 16, 2019 4:30 PM|PR Newswire|About: JNJ 

EVENITY™ (romosozumab)

Tecentriq Plus Chemotherapy (Abraxane and Carboplatin)

OPSUMIT® (Macitentan)

image271

Amgen And UCB Receive Positive Vote From FDA Advisory Committee In Favor Of Approval For EVENITY™ (romosozumab)

Wed January 16, 2019 5:41 PM|PR Newswire|About: AMGN, UCBJY 

Tecentriq Plus Chemotherapy (Abraxane and Carboplatin)

Tecentriq Plus Chemotherapy (Abraxane and Carboplatin)

Tecentriq Plus Chemotherapy (Abraxane and Carboplatin)

image272

FDA Accepts Genentech’s Supplemental Biologics License Application for Tecentriq Plus Chemotherapy (Abraxane and Carboplatin) for the Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer

Thu January 17, 2019 1:00 AM|Business Wire|About: RHHBY 

Johnson & Johnson (JNJ)

BD (Becton, Dickinson and Company (BDX))

Johnson & Johnson (JNJ)

image274

Johnson & Johnson Completes Acquisition of Ci:z Holdings Co., Ltd.

Thu January 17, 2019 7:00 AM|PR Newswire|About: JNJ

seeking biotech alpha January 2019 insight

Alkermes plc (ALKS)

Alkermes plc (ALKS)

ALRN-6924 in Combination with Pfizer’s IBRANCE® (palbociclib)

image278

Alkermes Announces Recipients of 1st Annual ALKERMES PATHWAYS RESEARCH AWARDS (SM) Program

Wed January 16, 2019 7:00 AM|PR Newswire|About: ALKS 

ALRN-6924 in Combination with Pfizer’s IBRANCE® (palbociclib)

ALRN-6924 in Combination with Pfizer’s IBRANCE® (palbociclib)

ALRN-6924 in Combination with Pfizer’s IBRANCE® (palbociclib)

image279

 Aileron up 35% on advancement of ALRN-6924 + Ibrance study

Jan. 16, 2019 1:15 PM ET|About: Aileron Therapeutics (ALRN)|By: , SA News Editor 

EVINITY (romosozumab)

ALRN-6924 in Combination with Pfizer’s IBRANCE® (palbociclib)

INGREZZA® (valbenazine)

image280

FDA advisory committees back Amgen's romosozumab

Jan. 16, 2019 3:50 PM ET|About: Amgen Inc. (AMGN)|By: , SA News Editor 

INGREZZA® (valbenazine)

ALRN-6924 in Combination with Pfizer’s IBRANCE® (palbociclib)

INGREZZA® (valbenazine)

image281

 New INGREZZA® (valbenazine) Analysis Published in the Journal of Affective Disorders Demonstrates Sustained Improvement in Tardive Dyskinesia Symptoms in Patients with Primary Mood Disorders

Wed January 16, 2019 4:01 PM|PR Newswire|About: NBIX 

seeking biotech alpha January 2019 insight

Medtronic plc (MDT)

Roche (SIX: RO, ROG; OTCQX: RHHBY)

Roche (SIX: RO, ROG; OTCQX: RHHBY)

image283

Medtronic Launches Mobile App That Communicates Directly with World's First Smartphone-Connected Pacemakers

Tue January 15, 2019 10:00 AM|InPublic US|About: MDT 

Combination BRAFTOVI®, MEKTOVI® and ERBITUX®

Combination BRAFTOVI®, MEKTOVI® and ERBITUX®

Combination BRAFTOVI®, MEKTOVI® and ERBITUX®

image285

Array BioPharma Announces 15.3 Months Median Overall Survival from the Safety Lead-in of the Phase 3 BEACON CRC Trial of the Combination BRAFTOVI®, MEKTOVI® and ERBITUX® in BRAF-Mutant Metastatic Colorectal Cancer

Mon January 14, 2019 5:03 PM|PR Newswire|About: ARRY 

ERLEADA (apalutamide)

Combination BRAFTOVI®, MEKTOVI® and ERBITUX®

ERLEADA (apalutamide)

image286

 J&J's Erleada OK'd in Europe for certain prostate cancer patients

Jan. 16, 2019 8:56 AM ET|By: , SA News Editor 

Allergan plc (AGN)

Combination BRAFTOVI®, MEKTOVI® and ERBITUX®

ERLEADA (apalutamide)

image287

CoolSculpting® and Sonja Morgan Partner To Get Real About Self-Care

Tue January 15, 2019 7:45 AM|PR Newswire|About: AGN 

seeking biotech alpha January 2019 insight

Adacel® (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine Adsorbed)

Adacel® (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine Adsorbed)

Adacel® (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine Adsorbed)

image288

 FDA Approves Expanded Use of Adacel® (Tdap) Vaccine for Repeat Vaccination

Mon January 14, 2019 4:47 PM|PR Newswire|About: SNY 

KEYTRUDA® (pembrolizumab)

Adacel® (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine Adsorbed)

Adacel® (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine Adsorbed)

image289

 Merck’s KEYTRUDA® (pembrolizumab) Reduced Risk of Death by 31 Percent Compared to Chemotherapy in Previously Treated Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Expressed PD-L1 (CPS ≥10)

Mon January 14, 2019 5:00 PM|Business Wire|About: MRK 

CABOMETYX® (cabozantinib)

Adacel® (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccine Adsorbed)

QuantiFERON®-TB Gold Plus (QFT®-Plus)

image290

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma

Mon January 14, 2019 5:38 PM|Business Wire|About: EXEL 

Intrexon Corporation (NASDAQ: XON) ("Intrexon (XON)")

Intrexon Corporation (NASDAQ: XON) ("Intrexon (XON)")

Intrexon Corporation (NASDAQ: XON) ("Intrexon (XON)")

image293

 Intrexon Partners with Next Green Wave to Advance Intrexon's Botticelli™ Next Generation Plant Propagation Platform into Development for Cannabis

Tue January 15, 2019 7:30 AM|PR Newswire|About: NXGWF, XON 

seeking biotech alpha January 2019 insight

tafamidis

Heat Biologics, Inc. (HTBX)

Heat Biologics, Inc. (HTBX)

image294

US FDA Accepts Regulatory Submissions for Review of Tafamidis to Treat Transthyretin Amyloid Cardiomyopathy

Mon January 14, 2019 8:00 AM|Business Wire|About: PFE 

Heat Biologics, Inc. (HTBX)

Heat Biologics, Inc. (HTBX)

Heat Biologics, Inc. (HTBX)

image295

 Heat Biologics Doses First Patient in New Cohort of its Expanded Phase 2 Trial of HS-110 in Combination with Merck's KEYTRUDA(R) in Non-Small Cell Lung Cancer Trial

Mon January 14, 2019 8:00 AM|Accesswire|About: BMY, HTBX, MRK 

 www.heatbio.com

Abbott (ABT)

Heat Biologics, Inc. (HTBX)

Varian (VSEA) (NYSE: VAR)

image296

FDA Approves World's First Device for Treatment of Premature Babies and Newborns with an Opening in Their Hearts (a Common Congenital Defect)

Mon January 14, 2019 9:00 AM|PR Newswire|About: ABT 

seeking biotech alpha January 2019 insight

Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg)

Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg)

Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg)

image300

 

January 08, 2019

Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Epclusa® (Sofosbuvir/Velpatasvir)

- Epclusa is the First Approved Treatment for Adults with Chronic Hepatitis C Virus with Decompensated Cirrhosis in Japan -

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan. 8, 2019-- Gilead Sciences, Inc. (NASDAQ: GILD)

crizanlizumab

Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg)

Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg)

image301

FDA tags Novartis' crizanlizumab a Breakthrough Therapy for sickle cell pain crises

Jan. 8, 2019 6:26 AM ET|About: Novartis AG (NVS)|By: , SA News Editor 

MINNEBRO™ (Esaxerenone)

Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg)

MINNEBRO™ (Esaxerenone)

image302

 Exelixis’ Collaborator Daiichi Sankyo Receives Regulatory Approval For MINNEBRO™ (Esaxerenone) Tablets for the Treatment of Hypertension in Japan

Tue January 8, 2019 6:00 AM|Business Wire|About: EXEL

ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (EXEL)

Boston Scientific Corporation (BSX)

revenues $3.724B (+19%). Da Vinci procedures up 18%, surpassing 1M/year - Shipments up 35% to 926.

revenues $3.724B (+19%). Da Vinci procedures up 18%, surpassing 1M/year - Shipments up 35% to 926.

image304

 Boston Scientific Announces Preliminary Unaudited Sales for the Fourth Quarter and Full Year 2018

Tue January 8, 2019 6:30 AM|PR Newswire|About: BSX

MARLBOROUGH, Mass., Jan. 8, 2019 /PRNewswire/ -- Boston Scientific Corporation (BSX

revenues $3.724B (+19%). Da Vinci procedures up 18%, surpassing 1M/year - Shipments up 35% to 926.

revenues $3.724B (+19%). Da Vinci procedures up 18%, surpassing 1M/year - Shipments up 35% to 926.

revenues $3.724B (+19%). Da Vinci procedures up 18%, surpassing 1M/year - Shipments up 35% to 926.

image305

 Intuitive Surgical Announces Preliminary Fourth Quarter and Full Year 2018 Results

Wed January 9, 2019 9:05 AM|GlobeNewswire|About: ISRG

SUNNYVALE, Calif., Jan. 09, 2019 (GLOBE NEWSWIRE) -- Intuitive Surgical, Inc. (ISRG) (“Intuitive”) (Nasdaq: ISRG)